Press Releases

Press Releases

Date Title
04/23/21 Vaxart Appoints David Wheadon, M.D., to its Board of Directors
SOUTH SAN FRANCISCO, Calif. , April 23, 2021 (GLOBE NEWSWIRE) -- Vaxart , Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the appointment of David Wheadon , M.D., to its Board
04/22/21 Poll: Oral Covid-19 Vaccine Pill Offers a Way to Overcome Vaccine Resistance of Millions of Americans
Nearly 19 million Americans who will decline vaccines would get vaccinated if they had a pill option, Vaxart’s poll finds Seven in 10 said they would prefer a pill over an injection SOUTH SAN FRANCISCO, Calif. , April 22, 2021 (GLOBE NEWSWIRE) -- Nearly 19 million more American adults – about a
03/04/21 Vaxart to Present at the H.C. Wainwright Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif. , March 04, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that management will present at the H.C.
02/25/21 Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
VXA-CoV2-1 oral COVID-19 vaccine candidate targeting both the S and N proteins is planned to advance to Phase 2 testing during Q2 2021 Cash and cash equivalents of $126.9 million as of December 31, 2020 Conference call and webcast focused on our COVID-19 strategy scheduled for Tuesday, March 2,
02/24/21 Vaxart to Provide 2021 Business Outlook on Tuesday, March 2, 2021
SOUTH SAN FRANCISCO, Calif. , Feb. 24, 2021 (GLOBE NEWSWIRE) -- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that it will host a conference call and provide a business update at
02/03/21 Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
Study reached primary and secondary endpoints of safety and immunogenicity, respectively VXA-CoV2-1 induced potent CD8 + T-cell responses VXA-CoV2-1 potentially protective against new and emerging COVID-19 strains Data to be presented today at the New York Academy of Sciences Symposium “The Quest
01/27/21 Vaxart Announces Publication of a Peer-reviewed Journal Article Showing the Potential Clinical and Economic Value of a Norovirus Vaccine
A computational simulation model showed that a norovirus vaccine costing as much as $1,300 can still be cost saving in children under 5 The model also showed a norovirus vaccine costing $100 can be cost saving in older adults SOUTH SAN FRANCISCO, Calif. , Jan.
01/26/21 Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data and Publication
New pre-clinical histology data show that Vaxart’s oral vaccine protected against lung inflammation in hamster models An article published in Nature Medicine reports data from a collaboration with Stanford University researchers on in vitro activity of Vaxart’s COVID-19 vaccine Data from Vaxart’s